Bellevue Group Ag Arcellx, Inc. Transaction History
Bellevue Group Ag
- $5.02 Billion
- Q4 2024
A detailed history of Bellevue Group Ag transactions in Arcellx, Inc. stock. As of the latest transaction made, Bellevue Group Ag holds 3,000 shares of ACLX stock, worth $207,990. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,000
Previous 4,000
25.0%
Holding current value
$207,990
Previous $334,000
31.74%
% of portfolio
0.0%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding ACLX
# of Institutions
224Shares Held
45.1MCall Options Held
434KPut Options Held
433K-
Paradigm Biocapital Advisors LP New York, NY4.37MShares$303 Million12.7% of portfolio
-
Nea Management Company, LLC Timonium, MD3.75MShares$260 Million20.37% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$244 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY3.48MShares$241 Million8.84% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.33MShares$231 Million0.0% of portfolio
About Arcellx, Inc.
- Ticker ACLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,819,200
- Market Cap $3.04B
- Description
- Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...